These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 29848702)

  • 1. Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells.
    Isono M; Sato A; Asano T; Okubo K; Asano T
    Anticancer Res; 2018 Jun; 38(6):3493-3500. PubMed ID: 29848702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ritonavir Interacts With Belinostat to Cause Endoplasmic Reticulum Stress and Histone Acetylation in Renal Cancer Cells.
    Isono M; Sato A; Okubo K; Asano T; Asano T
    Oncol Res; 2016; 24(5):327-335. PubMed ID: 27712589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
    Sato A; Asano T; Ito K; Asano T
    Urology; 2012 Apr; 79(4):966.e13-21. PubMed ID: 22296623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress.
    Okubo K; Isono M; Asano T; Sato A
    Anticancer Res; 2018 Oct; 38(10):5615-5626. PubMed ID: 30275179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells.
    Okubo K; REßING N; Schulz WA; Hansen FK; Asano T; Sato A
    Anticancer Res; 2021 Dec; 41(12):5987-5996. PubMed ID: 34848452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.
    Sato A; Asano T; Isono M; Ito K; Asano T
    BMC Urol; 2014 Aug; 14():71. PubMed ID: 25176354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically by Inducing Endoplasmic Reticulum Stress.
    Sato A; Asano T; Okubo K; Isono M; Asano T
    Oncol Res; 2018 Mar; 26(2):323-332. PubMed ID: 28560953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lopinavir-Ritonavir Combination Induces Endoplasmic Reticulum Stress and Kills Urological Cancer Cells.
    Okubo K; Isono M; Asano T; Sato A
    Anticancer Res; 2019 Nov; 39(11):5891-5901. PubMed ID: 31704813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis.
    Wang M; Liang L; Lu J; Yu Y; Zhao Y; Shi Z; Li H; Xu X; Yan Y; Niu Y; Liu Z; Shen L; Zhang H
    Thorac Cancer; 2019 Apr; 10(4):918-929. PubMed ID: 30883017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation.
    Sato A; Asano T; Okubo K; Isono M; Asano T
    Cancer Sci; 2017 Jun; 108(6):1194-1202. PubMed ID: 28342223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.
    Zou Y; Wang J; Leng X; Huang J; Xue W; Zhang J; Huang Y
    Oncotarget; 2017 Mar; 8(13):20825-20833. PubMed ID: 28212559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.
    Qian G; Yao W; Zhang S; Bajpai R; Hall WD; Shanmugam M; Lonial S; Sun SY
    Cancer Lett; 2018 Oct; 435():44-54. PubMed ID: 30059709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
    Sanchez E; Li M; Li J; Wang C; Chen H; Jones-Bolin S; Hunter K; Ruggeri B; Berenson JR
    Leuk Res; 2012 Nov; 36(11):1422-7. PubMed ID: 22906694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis.
    Kraus M; Malenke E; Gogel J; Müller H; Rückrich T; Overkleeft H; Ovaa H; Koscielniak E; Hartmann JT; Driessen C
    Mol Cancer Ther; 2008 Jul; 7(7):1940-8. PubMed ID: 18645004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
    Seavey MM; Lu LD; Stump KL; Wallace NH; Ruggeri BA
    Int Immunopharmacol; 2012 Jan; 12(1):257-70. PubMed ID: 22178195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.
    Sato A; Asano T; Ito K; Asano T
    Int J Oncol; 2012 Jul; 41(1):46-52. PubMed ID: 22470109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
    Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
    Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
    Sato A; Asano T; Ito K; Sumitomo M; Asano T
    BJU Int; 2012 Apr; 109(8):1258-68. PubMed ID: 21895936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
    Abt D; Besse A; Sedlarikova L; Kraus M; Bader J; Silzle T; Vodinska M; Slaby O; Schmid HP; Engeler DS; Driessen C; Besse L
    BJU Int; 2018 Apr; 121(4):600-609. PubMed ID: 29161753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells.
    Okubo K; Isono M; Miyai K; Asano T; Sato A
    Cancer Sci; 2020 Jan; 111(1):112-126. PubMed ID: 31675763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.